Co-delivery of triamcinolone acetonide and verapamil for synergistic treatment of hypertrophic scars via carboxymethyl chitosan and Bletilla striata polysaccharide-based microneedles

Zhang, Nan; Xue, Lingping; Younas, Ayesha; Liu, Fen-Fen; Sun, Junhong; Dong, Zhuolin; Zhao, Yongxing

doi:10.1016/j.carbpol.2022.119219

Cited by 43 publications

(38 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MNs were completely dissolved in 40 min, delivering a model drug at the same time, meeting the rapid dissolving requirements for hypertrophic scar application. Its efficacy was also tested using the rabbit hypertrophic scar model, showing a decrease in scar thickness and the expression of hydroxyproline and TGF-β1 [ 112 ].…”

Section: Microneedlesmentioning

confidence: 99%

Co-Encapsulation of Drugs for Topical Application—A Review

et al. 2023

View full text Add to dashboard Cite

Achieving the best possible outcome for the therapy is the main goal of a medicine. Therefore, nanocarriers and co-delivery strategies were invented to meet this need, as they can benefit many diseases. This approach was applied specifically for cancer treatment, with some success. However, these strategies may benefit many other clinical issues. Skin is the largest and most exposed organ of the human body, with physiological and psychological properties. Due to its exposition and importance, it is not difficult to understand how many skin diseases may impact on patients’ lives, representing an important burden for society. Thus, this review aims to summarize the state of the art in research concerning nanocarriers and co-delivery strategies for topical agents’ applications targeting skin diseases. The challenge for the medicine of the future is to deliver the drug with spatial and temporal control. Therefore, the co-encapsulation of drugs and the appropriate form of administration for them are so important and remain as unmet needs.

show abstract

Section: Microneedlesmentioning

confidence: 99%

Co-Encapsulation of Drugs for Topical Application—A Review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…According to the UV–vis measurement results, the TA doses encapsulated in DMN shafts were 104.4 ± 6.5 μg, which accounted for ∼4.92 wt % of the weight of the DMN shaft. This high TA loading in TAMN could be explained by the fact that TAMN was entirely fabricated by the high TA dose-loaded TA/HPCD IC without using any other matrix materials. , …”

Section: Resultsmentioning

confidence: 99%

Supramolecular Dissolving Microneedle Patch Loading Hydrophobic Glucocorticoid for Effective Psoriasis Treatment

Wang

Liu

et al. 2023

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Glucocorticoid-based creams are commonly used for treatments of psoriatic skin lesions while showing poor permeation because the thickened stratum corneum severely limits drug absorption. Although dissolving microneedle (DMN) patches have been employed in treating skin disease by virtue of their direct target to the lesion site, conventional DMN patches are generally fabricated from the water-soluble matrix, making them difficult to efficiently encapsulate hydrophobic glucocorticoids. Here, we develop a mechanically robust supramolecular DMN composed of hydroxypropyl β-cyclodextrin (HPCD) to effectively and uniformly load triamcinolone acetonide (TA). The TA-loaded HPCD DMN (TAMN) exhibits excellent mechanical performance that can easily pierce the thickened psoriasis lesions and deliver TA efficiently. Owing to the increased water solubility and bioavailability of TA after inclusion into HPCD, TAMN shows a superior in vitro inhibitory effect on immortalized human keratinocyte (HaCaT) cells. Importantly, the administration of TAMN twice a week effectively alleviates psoriatic signs and reduces the expression of Ki67, IL-23, and IL-17 in the ear lesions of imiquimod-induced psoriasis-like mice. This supramolecular DMN provides a promising strategy for the efficient treatment of psoriasis and other skin diseases, greatly broadens the applications of supramolecular materials in transdermal drug delivery, and widens the range of drugs in DMNs.

show abstract

“…The MN decreased the expression of the transforming growth factor-beta 1 (TGF-β1) and hydroxyproline (HYP) in HSs. The combination of TA and VRP showed a synergistic effect on the treatment of HSs [ 174 ].…”

Section: Polysaccharide Based Drug Delivery For Diseases Therapeuticsmentioning

confidence: 99%

Polysaccharide-Based Transdermal Drug Delivery

Xiang

Zhang

et al. 2022

Pharmaceuticals

View full text Add to dashboard Cite

Materials derived from natural plants and animals have great potential for transdermal drug delivery. Polysaccharides are widely derived from marine, herbal, and microbial sources. Compared with synthetic polymers, polysaccharides have the advantages of non-toxicity and biodegradability, ease of modification, biocompatibility, targeting, and antibacterial properties. Currently, polysaccharide-based transdermal drug delivery vehicles, such as hydrogel, film, microneedle (MN), and tissue scaffolds are being developed. The addition of polysaccharides allows these vehicles to exhibit better-swelling properties, mechanical strength, tensile strength, etc. Due to the stratum corneum’s resistance, the transdermal drug delivery system cannot deliver drugs as efficiently as desired. The charge and hydration of polysaccharides allow them to react with the skin and promote drug penetration. In addition, polysaccharide-based nanotechnology enhances drug utilization efficiency. Various diseases are currently treated by polysaccharide-based transdermal drug delivery devices and exhibit promising futures. The most current knowledge on these excellent materials will be thoroughly discussed by reviewing polysaccharide-based transdermal drug delivery strategies.

show abstract

Co-delivery of triamcinolone acetonide and verapamil for synergistic treatment of hypertrophic scars via carboxymethyl chitosan and Bletilla striata polysaccharide-based microneedles

Cited by 43 publications

References 22 publications

Co-Encapsulation of Drugs for Topical Application—A Review

Co-Encapsulation of Drugs for Topical Application—A Review

Supramolecular Dissolving Microneedle Patch Loading Hydrophobic Glucocorticoid for Effective Psoriasis Treatment

Polysaccharide-Based Transdermal Drug Delivery

Contact Info

Product

Resources

About